TY - CHAP M1 - Book, Section TI - Bronchogenic Carcinoma A1 - Wang, Sunny A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. PY - 2023 T2 - Current Medical Diagnosis & Treatment 2023 AB - Key Clinical Updates in Bronchogenic CarcinomaThe FDA approved sotorasib (AMG 510) for the treatment of KRAS G12C mutated lung cancers after progression on first-line treatment.Atezolizumab (PD-L1 inhibitor) can be given for 1 year post–adjuvant chemotherapy for resected stage II to IIIA NSCLC, based on a phase 3 trial showing improvement in disease-free survival compared with adjuvant chemotherapy without atezolizumab. For stage III NSCLCs, a phase 3 trial has shown improved survival outcomes by adding durvalumab (PD-L1 inhibitor) as consolidation therapy post–definitive chemoradiation.Five-year follow-up data for patients with 50% or greater PD-L1 expression show that patients who received pembrolizumab versus chemotherapy alone had improved median overall survival of 26 months versus 13 months.Skoulidis F et al. N Engl J Med. [PMID: 34096690]Reck M et al. J Clin Oncol. [PMID: 33872070]Felip E et al. Lancet. [PMID: 34555333] SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1193162102 ER -